Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28161039 | 0.80 | TP53 (0.34) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL10251781 | 0.76 | ADH1A (0.39) | — | |
| SCHEMBL27630994 | 0.74 | TP53 (0.33) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL104059 | 0.74 | ADH1A (0.36) | — | |
| SCHEMBL27651505 | 0.72 | TP53 (0.30) | TP53 | |
| SCHEMBL7457093 | 0.71 | SHBG (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL10772891 | 0.70 | ADH1A (0.33) | TP53SHBG | |
| SCHEMBL25775271 | 0.69 | SLC29A1 (0.31) | SLC29A1 | |
| SCHEMBL27651502 | 0.69 | — | — | |
| SCHEMBL25058914 | 0.69 | CHRNB2 (0.39) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459550-B2 | Process for the preparation of Cefditoren | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2008-12-02 | — | — | US | claimed |
| US-20060173175-A1 | Process for the preparation of cefditoren | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2006-08-03 | — | — | US | claimed |
| WO-2005003141-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF CEFDITOREN | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2005-01-13 | — | — | WO | claimed |
| CN-101903469-B | Thermoplastic polyamides having polyether amines | BASF SE | 2014-08-20 | — | — | CN | disclosed |
| US-8481652-B2 | Thermoplastic polyamides having polyether amines | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| CN-101977996-B | Polyamide nanocomposites with hyper-branched polyetheramines | BASF SE | 2013-01-02 | — | — | CN | disclosed |
| CN-102037079-A | Polyamide nanocomposites with hyper-branched polyethylenimines | BASF SE | 2011-04-27 | — | — | CN | disclosed |
| CN-101977996-A | Polyamide nanocomposites with hyper-branched polyetheramines | BASF SE | 2011-02-16 | — | — | CN | disclosed |
| US-20110021686-A1 | POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHERAMINES | BASF SE (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021687-A1 | POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHYLENEIMINES | BASF SE (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110009566-A1 | THERMOPLASTIC POLYAMIDES HAVING POLYETHER AMINES | BASF SE (DE) | 2011-01-13 | — | — | US | disclosed |
| CN-101903469-A | Thermoplastic polyamides having polyether amines | BASF SE | 2010-12-01 | — | — | CN | disclosed |
| US-7459550-B2 | Process for the preparation of Cefditoren | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2008-12-02 | — | — | US | disclosed |
| US-20060173175-A1 | Process for the preparation of cefditoren | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2006-08-03 | — | — | US | disclosed |
| WO-2005003141-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF CEFDITOREN | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173175-A1 | Process for the preparation of cefditoren | DHPS, FDPS, CYP4F2 | TP53 4176/4885KDM4E 673/4885GMNN 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.